Compare ATS & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATS | WVE |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2023 | 2015 |
| Metric | ATS | WVE |
|---|---|---|
| Price | $30.99 | $12.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 16 |
| Target Price | ★ $35.00 | $30.44 |
| AVG Volume (30 Days) | 183.5K | ★ 3.2M |
| Earning Date | 02-04-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $2,048,319,324.00 | $109,230,000.00 |
| Revenue This Year | $16.92 | N/A |
| Revenue Next Year | $5.13 | $16.10 |
| P/E Ratio | $221.51 | ★ N/A |
| Revenue Growth | 1.80 | ★ 103.75 |
| 52 Week Low | $20.90 | $5.28 |
| 52 Week High | $32.73 | $21.73 |
| Indicator | ATS | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 41.05 |
| Support Level | $30.21 | $12.51 |
| Resistance Level | $31.83 | $14.15 |
| Average True Range (ATR) | 1.20 | 0.76 |
| MACD | 0.16 | -0.04 |
| Stochastic Oscillator | 85.33 | 8.29 |
ATS Corp is a Canada-based company that provides automation systems. The company designs and builds customized automated manufacturing and testing systems for customers, and provides pre- and post-automation services. The company's products comprise conveyor systems, automated electrified monorails, tray handlers, laser systems, and other hardware and software products. The company also provides pre-automation solutions, including strategic direction and planning services, as well as aftermarket support. The company's clients come from the life sciences, food and beverage transportation, consumer products and electronics, and energy sectors. The company generates the majority of its sales from the North American and European markets.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.